![](https://www.diabetesnews.com/wp-content/uploads/2021/03/technology-3083500_640-150x150.jpg)
SGLT-2 inhibitors like sotagliflozin are antihyperglycemic agents approved in the US for use in patients with type 2 diabetes. However, sotagliflozin is also approved for type 1 diabetes in Europe, and studies have shown that using sotagliflozin along with insulin has benefits in patients with type 1 diabetes. Read more